IL17A and hepatocellular carcinoma: Experiments using murine HCC models demonstrated that NCR-ILC3s produce IL-23-mediated IL-17, inhibiting specifically CD8+ T cell immunity by promoting lymphocyte apoptosis and thus inducing HCC development (51) (Figure 2).